

1 **The comparison of vaccine hesitancy of COVID-19 vaccination in China and the United States**

2
3 Taoran Liu^{1¶}, Zonglin He^{2¶}, Jian Huang^{3,4}, Ni Yan¹, Qian Chen¹, Fengqiu Huang¹, Yuejia Zhang⁵,
4 Omolola M Akinwunmi^{6,7}, Babatunde Akinwunmi^{8,9}, Casper J.P Zhang¹⁰, Yibo Wu^{11,12*}, Wai-Kit
5 Ming^{1*}

6
7 ¹Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, China

8 ²International School, Jinan University, China

9 ³Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research
10 (A*STAR), Singapore

11 ⁴Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial
12 College London, London, the United Kingdom

13 ⁵School of Medicine, Jinan University, China

14 ⁶Department of Radiology, College of Medicine, University of Ibadan Nigeria, Nigeria

15 ⁷Department of Radiology, University College Hospital Ibadan, Oyo State Nigeria, Nigeria

16 ⁸Department of Obstetrics and Gynecology Brigham and Women's Hospital Boston, the United States

17 ⁹Center for Genomic Medicine (CGM), Massachusetts General Hospital, Harvard Medical School
18 Harvard University, Boston, the United States

19 ¹⁰School of Public Health, The University of Hong Kong, Hong Kong

20 ¹¹Key Research Base of Philosophy and Social Sciences in Shaanxi Province, Health Culture Research
21 Center of Shaanxi, Xi'an, China

22 ¹²Peking University Health Science Center, Beijing, China

23
24 [¶] These authors contributed equally to this work

25
26 * Corresponding author

27 Wai-Kit Ming, Professor, MD, PhD, MPH, MMSc, EMBA

28 Department of Public Health and Preventive Medicine School of Medicine

29 Jinan University

30 601 Huangpu W Ave, Tianhe District

31 Guangzhou, Guangdong Province, 510632

32 China

33 Tel: +86 85228852

34 Email: wkming@alumni.harvard.edu

35
36 *Co-corresponding author

37 Yibo Wu, MPharm, Professor

38 Key Research Base of Philosophy and Social Sciences in Shaanxi Province, Health Culture Research

39 Center of Shaanxi, Xi'an, China

40 Peking University Health Science Center, Beijing, China

41 Phone: +86 18810169630

42 Email: bjmuwuyibo@outlook.com

43 **Abstract**

44

45 **Objectives:** To investigate the differences in vaccine hesitancy and preference of the currently available
46 COVID-19 vaccines between two countries, viz. China and the United States (US).

47

48 **Method:** A cross-national survey was conducted in both China and the US, and discrete choice
49 experiments as well as Likert scales were utilized to assess vaccine preference and the underlying
50 factors contributing to the vaccination acceptance. A propensity score matching (PSM) was performed
51 to enable a direct comparison between the two countries.

52

53 **Results:** A total of 9,077 (5,375 and 3,702, respectively, from China and the US) respondents have
54 completed the survey. After propensity score matching, over 82.0% respondents from China positively
55 accept the COVID-19 vaccination, while 72.2% respondents from the US positively accept it.
56 Specifically, only 31.9% of Chinese respondents were recommended by a doctor to have COVID-19
57 vaccination, while more than half of the US respondents were recommended by a doctor (50.2%), local
58 health board (59.4%), or friends and families (64.8%). The discrete choice experiments revealed that
59 respondents from the US attached the greatest importance to the efficacy of COVID-19 vaccines
60 (44.41%), followed by the cost of vaccination (29.57%), whereas those from China held a different
61 viewpoint that the cost of vaccination covers the largest proportion in their trade-off (30.66%), and
62 efficacy ranked as the second most important attribute (26.34%). Also, respondents from China tend to
63 concerned much more about the adverse effect of vaccination (19.68% vs 6.12%) and have lower
64 perceived severity of being infected with COVID-19.

65

66 **Conclusion:** While the overall acceptance and hesitancy of COVID-19 vaccination in both countries are
67 high, underpinned distinctions between countries are observed. Owing to the differences in COVID-19
68 incidence rates, cultural backgrounds, and the availability of specific COVID-19 vaccines in two
69 countries, the vaccine rollout strategies should be nation-dependent.

70

71 **Key words:** Global health; COVID-19; Vaccine hesitancy; Public health; Health policy; Vaccine
72 preference

73

74

75
76
77
78

79 **Introduction**

80 A pneumonia-like disease outbreak, now named the 2019 Coronavirus disease (COVID-19) caused by a
81 newly identified coronavirus, a.k.a., the severe acute respiratory syndrome (SARS)-CoV-2, has swept
82 the globe in early 2020¹. Although its exact origin remains unknown, and detailed knowledge of its
83 transmission is still limited, this global pandemic has become the most serious public health threat from
84 a respiratory virus since the 1918 H1N1 influenza pandemic²⁻⁴. One year after the commencement of the
85 pandemic⁵, the COVID-19 is continuously imposing tremendous burdens on the public health systems
86 and the economy globally^{6,7}. As of early March 2021, 219 countries or regions have reported confirmed
87 cases⁸, with over 120 million confirmed cases and over 2.66 million deaths, and a case fatality rate over
88 2.21% worldwide⁹.

89 Various public health measures, specifically, non-pharmaceutical interventions (NPIs) that showed
90 effectiveness in previous infection outbreaks (e.g., mass facemask use, social distancing, and home
91 quarantine) have been implemented by governments to contain the spread of SARS-CoV-2^{2,10-12}. While
92 the effectiveness of these public health measures in this outbreak remains to be determined, these NPIs
93 may carry a high economic cost, leading to a long war of attrition in society¹³.

94 Therefore, massive vaccination coverage is considered as a prerequisite to achieve herd immunity and
95 therefore curb the COVID-19 pandemic¹⁴. By March 2021, several COVID-19 vaccines¹⁵⁻¹⁷ have been
96 developed and vaccination rollout has started in a few countries. However, people remain uncertain of
97 the safety and efficacy of the vaccines. This becomes extensive especially after reports of adverse events
98 secondary to shots of the mRNA vaccination¹⁸, sudden death secondary to shots of mRNA COVID-19
99 vaccines in Norway¹⁹, and incidences of inactivated vaccines during a phase 3 trial in Brazil, among
100 others^{20,21}. Also, according to a national poll in the US, only 58% of adults aged from 50 to 80 are
101 willing to receive COVID-19 vaccine²². Additionally, as the increasing number of variants have been
102 identified around the globe^{23,24}, the current vaccines may no longer provide effective protection against
103 SARS-CoV-2 virus including the variants.

104 Some studies have found that COVID-19 vaccines acceptance varied to a large extent across countries
105 and regions before the vaccine becomes available, and the vaccine hesitancy of COVID-19 is increasing
106 globally^{25,26}. This may influence the vaccination coverage and hinder the establishment of herd

107 immunity. Interestingly, an increasing vaccine hesitancy is being noticed among Chinese residents and
108 some Asian countries where the transmission of COVID-19 has been well-controlled, specifically, when
109 the vaccines are completely free in some countries, and such phenomena may be attributable to the low
110 perceived benefits of the vaccines and low perceived risks of the COVID-19 pandemic, and most
111 importantly, the low perceived efficacy and the increasingly high skepticism of the efficacy and safety
112 of the currently COVID-19 vaccines²⁷. Therefore, it is urgently to find the hindering factors and further
113 promote the COVID-19 vaccination to achieve the herd immunity.

114 Vaccine hesitancy is multifactorial, attributable to general misinformation spread, perceived risks of
115 disease, perceived efficacy and safety of vaccines, attitudes and demand of vaccines, cultural and
116 religious factors and other unspecific factors^{28,29}. China and the United States (US) are two of the
117 representative countries that are among the major countries hardest hit by the pandemic³⁰, and both have
118 large population but very different cultural and religious systems³¹; hence residents' acceptance to
119 COVID-19 vaccination of the two countries could be strategically significant for further vaccines
120 promotion and herd immunity.

121 Nevertheless, the direct comparison between countries could be biased and irrelevant owing to the
122 high heterogeneity and confounding effects, hence in the present study, the propensity score matching
123 (PSM) was utilized to compare the two population. And the following aims were addressed: 1) to
124 investigate on the census-level acceptance and preference of residents and further exploring the
125 influencing factors underlying their decision-making towards COVID-19 vaccination; 2) to compare the
126 two countries in a statistically comparable way to demonstrate the vaccine hesitancy in two countries
127 and further provide insights into future strategies of the large-scale COVID-19 vaccination coverage in
128 two countries.

129 **Materials and Methods**

131 *Study design*

132 An anonymous self-administered cross-sectional survey was conducted online in China and the US
133 through multiple international online panel providers (for data collecting in the US) and recruited
134 volunteers across China (for data collecting in China), and stratified sampling was used, and nationally
135 representative samples of the general adult populations were collected³². The questionnaire was
136 established in Lighthouse studio (Sawtooth Software, version 9.8.1). The study was approved by the
137 Jinan University Institutional Review Board. In the survey, respondents responded to a total of 55 items

138 of questions, including standard demographic and socio-economic questions including age, sex, level of
139 education, annual income, and marital status, followed by one set of discrete choice experiments (DCE)
140 and questions about risk perception, COVID-19 impact, attitudes, and acceptance of and attitudes
141 towards vaccines against COVID-10 during the pandemic. Prior to formal data collection, a pilot study
142 in China had been conducted to evaluate the content validity and the reliability of the questions with
143 both experts and general populations, and a group of experts was consulted to improve semantics and
144 readability.

145

146 ***Respondents***

147 The inclusion criteria were respondents aged 18 years and above without cognitive impairments (self-
148 report). Respondents were randomly recruited and selected through multiple international online panel
149 providers (MTurk and Dynata) and by nearly 100 experienced volunteers recruited across China using a
150 stratified sampling method. No personally identifiable information was collected. A total of 12,959
151 respondents was recruited, with a total of 9077 respondents (5,375 and 3,702 respondents from China
152 and the US respectively) included in our study.

153

154 ***Data collection***

155 The survey data were collected between January 29 and February 13, 2021. The respondents were
156 required to provide a randomly generated code after completing the survey to ensure that the
157 respondents are real persons instead of robots. All the questions were close ended, with tick boxes
158 provided for responses and no question skipping allowed, and no data would be stored if the website of
159 the questionnaire was closed before completion. Hence, no missing data were generated.

160 General acceptance was defined as scoring greater than 6 with regards to answering the question
161 “How do you rate your willingness and acceptance to get COVID-19 vaccination? (if the vaccines are
162 generally available)”, and the *acceptance under social cues* was defined as scoring greater than 6 for the
163 acceptance for COVID-19 vaccines if the vaccination was recommended by the respondents’ family
164 members, friends or employers. Countries were categorized as developed and developing countries
165 according to United Nations country classification². Educational level was further classified into four
166 groups, where “low” signifies respondents reporting having not finished a secondary education (high
167 school); “medium” signifies those who had completed secondary, vocational, or equivalent degrees; and
168 “high” group consisted of those who had completed a tertiary or bachelor’s degree and “very high”

169 indicates postgraduate work. Moreover, two external COVID-19-related variables were added abided by
170 the Method reported by Lazarus et al., namely the total SARS-CoV-2 positive cases per million persons
171 and total SARS-CoV-2 deaths per million persons as reported by Worldometer on 21 January 2021^{1, 2}.
172 For COVID-19 cases per million in population, “High” was defined as more than 10,000 cases per
173 million people, “medium” as between 1,000 and 10,000 cases per million people, and “low” was defined
174 as below 1,000 cases per million people. For COVID-19-specific mortality cases per million in the
175 population, “High” was defined as more than 1,000 deaths per million people, “medium” as between
176 100 and 1,000 deaths per million people, and “low” was defined as below 100 deaths per million people.
177

178 *Survey design*

179 The questionnaire consists of three sections with a total of 55 items that required a response. In the first
180 section, respondents responded to provide social-demographic information regarding age, sex,
181 educational level, occupation, income level, nationality and marital status. Additionally, respondents
182 were required to rate their willingness and acceptance to get vaccinated from “totally unwilling” to
183 “totally willing” with and without social cues. And the questions were “How do you rate your
184 willingness and acceptance of getting vaccination?” and “How do you rate your willingness and
185 acceptance if your friends, family members, neighbors etc. recommend you do so?”, respectively. Also,
186 respondents responded to questions related to COVID-19 infection history as well as major source of
187 information with regard to COVID-19 vaccines.

188 In the second section, DCE was used to further explore respondents’ preference of the currently
189 available vaccines. Specifically, vaccine attributes and their levels were identified and retrieved through
190 relevant literature and several vaccines on the market, and the attributes were then ranked, categorized
191 and refined by a group of experts in the field of public health and vaccination^{3, 4}. A total of six attributes
192 were identified and a two-vaccine profile was randomly adopted for the DCE design. The detailed
193 description of the attributes and levels are summarized in Table S2. During the survey, respondents were
194 asked to make a series of hypothetical choices and estimate their preference for different attributes of the
195 vaccine based on scenarios.

196 In addition, to assess respondents’ attitudes toward COVID-19 and the acceptance of COVID-19
197 vaccination and their influencing factors, questions were designed based on the five-concept health
198 belief model and other frameworks, as reported by various previous studies to assess vaccine acceptance

199 and hesitancy for newly emerging infectious diseases such as H1N1, MERS or Ebola ⁵ (Figure S5). The
200 following contents were included in this section: (1) the perceived susceptibility to COVID-19 infection;
201 (2) perceived severity of COVID-19 infection, (3) perceived benefits of COVID-19 vaccination; (4)
202 perceived barriers to COVID-19 vaccination and (5) cues to action for COVID-19 vaccination, such as a
203 recommendation from a doctor or local health board, were assessed; (6) socio-economic factors; and (7)
204 past immunization behaviors ⁶. Most questions were assessed on a seven-point Likert scale. The
205 reliability ($\alpha = 0.8951$) and validity (Kaiser-Meyer-Olkin Measure = 0.942) of the Likert scale were
206 tested.

207

208 *Statistical analysis*

209 The data in this study were collected in an international cross-sectional survey. To minimize potential
210 confounding biases due to discrepancy in baseline characteristics, propensity scoring was calculated and
211 matched to balance covariates for respondents in China and in the United States. Propensity score
212 matching is a statistical technique that can help strengthen causal arguments in quasi-experimental and
213 observational studies by reducing selection bias³³. The covariates were identified using the pair-wise
214 Pearson correlation matrix, and the results were presented in the Table S3. Later, the set of covariates
215 was determined by at best minimizing the residual confounding factors, where a logistic regression
216 model was performed to estimate the propensity scores for each groups of respondents, and the covariate
217 imbalance testing was reported in the Table S5. Finally, a total of 3,436 respondents, with half from
218 China and the other half from the US, were matched using propensity scores from the total 12,959
219 respondents, with the covariates being sex, age, and annual income.

220 Descriptive statistics were performed to describe the characteristics of socio-economic status and
221 demographic information, risk perception, pandemic impact, as well as acceptance, attitudes and
222 preferences of COVID-19 vaccines, using central tendency (mean, median) and dispersion (standard
223 deviation, interquartile interval) measures. The Chi-square test or Fischer's exact test was used for the
224 univariate analysis of qualitative variables and Student's t-test or Mann Whitney test for quantitative
225 variables. Absolute and relative frequencies were presented for qualitative variables, while quantitative
226 variables were presented as mean (standard deviation). Multivariate logistic regression was then
227 performed between the vaccine demand group and vaccine delay group to identify the influencing
228 factors of vaccination acceptance (immediate or delayed acceptance), with the odds ratio (OR), standard

229 error (SE), and a 95% confidence interval (CI) being calculated. The data were analyzed using STATA,
230 version 14.0 (Stata Corp, College Station, TX, USA). For the DCE part, we performed a conditional
231 logit model (CLOGIT) to quantify respondents' preference for vaccines' attributes and levels in their
232 trade-off in general and to further explore participants' preference heterogeneity among different
233 countries and regions. After the conditional logit model, we dummy coded all the attribute levels with
234 the level least preferred selected as the reference level⁷. After dummy coding, the model parameter β
235 represents the value that respondents placed on an attribute level relative to the reference level, where
236 the model parameter β does not directly reflect the preference weight within an attribute this
237 presentation can enhance the interpretation of the preference weights specifying the difference between
238 two random coefficients. The data of the DCE part were analyzed using STATA, version 14.0 (Stata
239 Corp, College Station, TX, USA).

240

241 **Scenario analysis and simulation**

242 We also performed a scenario analysis and product simulation in Lighthouse studio (version 9.9.1) to
243 further explore vaccines with what characteristics most contributed to respondents' preference and with
244 most probability to be uptake. The base scenario was hypothesized based on the vaccines variety with
245 every attributes' levels being the lowest utilities (except cost attribute), while the best scenario was
246 assumed to have each attributes' levels being with the highest utilities (except cost attributes). And the
247 other scenarios were established according to the currently available information of vaccines from
248 various clinical trials. Also, we use share of preference as our simulation model since this model helped
249 us better predict the level of preference any vaccines might achieve. And the whole simulation were
250 done in two steps: 1) Subject the respondent's total utilities for the product to the exponential
251 transformation, specifically as $s = \exp(\text{utility})$, and 2) rescale the results to a total of 100%³⁴.

252

253 **Results**

254 ***Respondents' characteristics***

255 The present study conducted a large-scale self-administered online survey in China and US. A total of
256 9077 respondents (5,375 and 3,702 respondents from China and the US respectively), who have
257 completed the survey, were selected and further analyzed in the present study. Concerning the pre-PSM
258 samples, the respondents from the United States tended to be higher-educated and earning more money
259 annually compared to respondents from China. For the two respondent groups, the majority of the

260 respondents were female (55.3% for China, 51.8% for the US), and 47.8% of the respondents in China
261 and 67.6% of those in the US hold a bachelors' degree or higher. After PSM for age, sex, education,
262 annual income, and occupation, no statistically significant discrepancies could be discerned between the
263 respondents from the two countries in demographic characteristics ($P = 1.00$ for age, sex, education,
264 annual income and occupation).

265

266 ***Generate hesitancy and participants' vaccination history***

267 As pre-PSM listed in Table 1 and Fig 2, respondents from China showed a relatively lower hesitancy of
268 COVID-19 vaccines (7.8/10) than those from the US (7.2/10) when asked "How do you rate your
269 willingness and acceptance to get COVID-19 vaccination? (if the vaccines are generally available)"
270 (*general acceptance*). For post-PSM, over 82.0% respondents from China positively accept the COVID-
271 19 vaccination, while 72.2% respondents from the US positively accept it, and the proportion change to
272 83.3% and 71.0%, respectively, if the respondents were recommended to get vaccinated by friends,
273 family members or employers, etc. Additionally, around 12% respondents from China and 38.3% from
274 the US have ever delayed or cancelled vaccination for reasons other than illness or allergy, respectively.

275 Interestingly, for post-PSM, 31.9% of Chinese respondents were recommended by a doctor to get
276 COVID-19 vaccination, while more than half of the US respondents (50.2%) were recommended by a
277 doctor (Table S1). And generally, more than half of the US respondents were recommended to get
278 vaccination, either by local health board (59.4%), or by friends or families (64.8%).

279 The influence of demographic factors on the average rating of hesitancy of COVID-19 vaccination
280 between the two countries for were shown in Table S1, and the detailed subgroup analysis of the
281 hesitancy by sex, age intervals, education, occupation and annual income were shown in Figure S1-S5,
282 respectively. Also, proportion of vaccine hesitancy from China generally smaller than those from the US,
283 except for the respondents with a master's academic degree, or with an annual income over 70,000 USD,
284 or with a skilled, agricultural, forestry and fishery related occupations. In both China and the US,
285 respondents' vaccination hesitancy increased with the academic degree from bachelor's degree.
286 Moreover, being female and higher educated, as well as themselves being infected or friends or families
287 around being infected served as contributor for the respondents hesitating the vaccines, as shown in
288 Table S1.

289

290 ***Post-PSM participants' vaccine preference, attributes and level importance.***

291 The relative attributes' importance compared between the United States and China was shown in Figure
292 3. After PSM, we found respondents from the US attached the greatest importance to the efficacy of
293 COVID-19 vaccines (44.41%), followed by the cost of vaccination (29.57%), whereas those from China
294 hold a different viewpoint, the cost of vaccination covers the largest proportion in their trade-off
295 (30.66%), and efficacy ranked as the second most important attribute (26.34%). Additionally,
296 respondents from China also concerned much more about the adverse effects of the vaccines, which was
297 ranked as the third most important factor (19.68%). The duration of vaccination, vaccine varieties and
298 time for the vaccine starting to work remained a relative low importance in both countries.

299 Interestingly, in post-PSM result, respondents from the US preferred the mRNA COVID-19 vaccine,
300 while respondents from China prefer the inactivated COVID-19 vaccine (vs mRNA) (OR=1.164, 95%
301 CI (1.124, 1.205), $p < 0.001$). Also, respondents' vaccine preference significantly decreased with a
302 moderate adverse effect compared with a very mild adverse effect. In both countries, respondents'
303 preference increased along with the rise of efficacy, and reached a peak at 95% efficacy (vs 55%). The
304 reduction of vaccine preference only appeared in respondents from the US if the time for the vaccines
305 starting to work getting longer (20 days vs 5 days) (OR=0.893, 95% CI (0.849, 0.938), $p = 0.06$).
306 Moreover, respondents from both countries preferred a longer vaccine protection time and low level of
307 vaccination cost.

308 The post-PSM preference comparison between sex in both countries is showed in Figure S6. For
309 respondents from the US, first, both male and female respondents ranked the efficacy of COVID-19
310 vaccines as the most essential attribute, and the efficacy was even slightly more important for female
311 (male: 43.12%, female 45.07%). while for respondents from China, the cost of vaccination had the
312 greatest relative importance, and slightly more important for female (male: 28.85%, female: 31.45%).
313 Similarly, the efficacy of COVID-19 vaccines also accounted more for female respondents than male
314 respondents (male: 26.36%, female: 26.02%).

315

316 ***Post-PSM scenario analysis and uptake likelihood prediction***

317 Table 3 presented the simulated share of preference under nine different scenarios which were based on
318 clinical trials and real-world data of various COVID-19 vaccines, as reported by various large-scale

319 clinical trials. The base scenario is the vaccine with seemingly lower preference, and only 2.9% of the
320 respondents from the US will uptake the base scenario vaccine, while 4.5% of those from China prefers
321 to taking the base scenario vaccine. Still, we noticed that the US respondents are more likely to choose
322 mRNA vaccines (share of preference 14.2% for Scenario 2 and 17.3% for Scenario 3) while those from
323 China places higher preference in Inactivated vaccine (Scenario 4, share of preference 13.7%). But the
324 respondents from the US also have high share of preference for Adenovirus vaccine (Scenario 5) and the
325 Chinese respondents have high preference for mRNA vaccine too (Scenario 3, Share of preference
326 13.4%). If all the attributes of the vaccine were set as the best levels as indicated in the MNL analysis
327 (Scenario 8), then 19.1% and 17.6% of the respondents from the US and China respectively will choose
328 this hypothetical vaccine.

329

330 ***Behavioral and psychological results***

331 The Likert Scale, as presented in Table S1, indicated that generally, the respondents had a highly
332 positive attitude towards the benefits of COVID-19 vaccines (the US: 15.8/21; China: 17/21) and were
333 not so concerned about the risks and barriers of COVID-19 vaccination, although respondents from
334 China concerned slightly more about risks than those from the US (the US: 11.3/21; China: 13.3/21).
335 Also, the respondents generally believe in the necessity and efficacy of vaccination in the prevention of
336 diseases, as they rate high on the item “In general, vaccination is effective in preventing diseases” (the
337 US: 5.5/7.0; China: 5.7/7.0), followed by the scoring of 5.9/7.0 and 5.3/7.0 for respondents from China
338 and the US respectively, for item “In general, prevention is better than cure”. In terms of socio-cultural
339 factors, religion- and gender-related reasons were the least contributory to the decision-making of
340 COVID-19 vaccination (the US: 3.1/7.0; China: 4.2/7.0) for religious or cultural reasons, and (the US
341 4.4/7.0; China: 5.7/7.0 for gender reasons). Respondents rate the lowest score on the item “I believe that
342 people are risking their health or the health of the society if they do not take a COVID-19 vaccine” (the
343 US: 2.5/7.0; China: 3.5/7.0).

344

345 **Discussion**

346 The present study sought to provide a comprehensive investigation of the acceptance of COVID-19
347 vaccination in China and the United States and compare the hesitancy and preference of COVID-19
348 vaccines between the two countries controlling for demographic characteristics using PSM. The
349 unmatched samples of the respondents from the two countries were adjusted with uncontrolled quota

350 sampling method, hence the results may demonstrate the census-level investigation in two countries.
351 Generally, majority of the respondents in both countries had high acceptance regarding the COVID-19
352 vaccination, either general acceptance or acceptance under recommendation from friends, family or
353 employers.

354 In our study, we found that respondents from China have a relatively higher acceptance than those
355 from the US, and when compared to the studies conducted before the vaccine become available or even
356 before the results of clinical trials on some COVID-19 vaccines were available, their acceptance
357 increased respectively³⁵. Existing opinion polls for acceptance of a hypothetical COVID-19 vaccines of
358 US citizen ranged from 40% to 70%³⁶⁻³⁹. And a population-based survey conducted in Hong Kong,
359 China reported the overall vaccine acceptance rate was only 37.2%⁴⁰, while more than 90% of
360 respondents in mainland China would like to be vaccinated for COVID-19 vaccines regardless of the
361 efficacy, among whom³⁵. Although studies have reported that some perceived susceptibility to infection
362 or perceived risks may not be associated with the COVID-19 acceptance⁴⁰, our results showed that there
363 is distinct difference between the respondents from China and the US regarding the perceived risks of
364 infection and perceived benefits of vaccination after propensity score matching. The Chinese
365 respondents tended to be more concerned about the health problems COVID-19 may cause to them if
366 they were infected, while the US respondents are more concerned of being infected (Table S1). And
367 studies have found an association between the incidence of diseased population and perceived risks, and
368 low risk perception was also associated with the respondents trusting health professionals and health
369 officials for information on COVID-19⁴¹. Public concern about vaccine safety and efficacy has
370 frequently been reported as one of the major obstacles to vaccination acceptance, specifically when the
371 COVID-19 vaccines were being developed and rolled at an unprecedented speed⁴²⁻⁴⁷. But it is
372 noteworthy that, despite high acceptance of the vaccines, Chinese respondents were more concerned
373 about the safety of the vaccines, the adverse effect of the COVID-19 vaccines had a far more relative
374 importance for respondents from China than those from the US. And combined with their low perceived
375 risks of susceptibility, this may hence lead to their placing greater importance for the attribute “cost” in
376 the discrete choice experiment (Table 2 and Figure 2) and also may explain why the vaccination rate still
377 remains a relatively low level in China, compared with some other countries in the world, such as the
378 US, the UK, etc. As of March 31st, 2021, there are a total of 114.69 million doses of COVID-19
379 vaccination reported in China; however, the vaccination rate remains below 10%⁴⁸. There is still a huge
380 gap from achieving herd immunity, which requires 70% to 90% vaccination rate as some experts

381 estimated^{49,50}. In contrast, the vaccination rate in the US has reached 30% (at least one dose)⁵¹ with
382 103.35 million people receiving one or more doses cumulative. And therefore, although, vaccination
383 growth rate seems to be more rapid than the US from March 24, 2021, the speed is not rapid enough to
384 reach herd immunity in short term, eventually, the relative low level of vaccination rate in China may
385 force China to lose its advantage in COVID-19 epidemic control⁵². Therefore, improving the speed of
386 vaccination is a top priority currently for all countries around the world to terminate the pandemic.

387 In both pre-PSM and post-PSM samples, we found that while the respondents from China attached
388 more importance to cost, those from US attached more to efficacy. This finding may strongly correlate
389 with local COVID-19 incidence and mortality rate, namely the perceived risk for the public to be
390 infected. As of March 14, 2021, there are over 120 million cumulative COVID-19 cases and around 2.66
391 cumulative death⁹ in the US. Thus, vaccines with high efficacy are urgently needed to contain the
392 development of epidemic in the US, whereas in China, there are only more than 102 thousand
393 cumulative cases and around 5 thousand deaths⁹. Also, we found that respondents from the US prefer to
394 be vaccinated with mRNA vaccines, while respondents from China consider inactivated vaccines as the
395 best choice, this might be related to the actual availability of different types of vaccine in US and China.
396 High vaccination coverage depends on the public understanding of the need and value of vaccination,
397 the availability of vaccines as well as accessible immunization services⁵³. And to further promote high
398 vaccination coverage, the Strategic Advisory Group of Experts (SAGE) on Immunization Working
399 Group on Vaccine Hesitancy recommends three categories of strategies, namely the increase of
400 understanding of vaccine hesitancy, establishment of structures and organizational capacity at global,
401 national and local levels, as well as international collaboration between countries regarding the
402 development, validation, and implementation of new tools to address hesitancy^{53,54}. Also, our study
403 emphasizes the key role of international collaboration. Humans have been fighting for the many
404 centuries, and the formal collaboration has been institutionalized through World Health Organization
405 (WHO). However, in this COVID-19 pandemic, many countries showed poor performance against
406 COVID-19 with reflection of strong self-interested nationalism⁵⁵. The nationalism has greatly restricted
407 international collaboration, and further hindered the epidemic control. Meanwhile, vaccine nationalism
408 has been warned by WHO as a moral failure. Therefore, to relieve the global epidemic, collaboration on
409 vaccine were urgently needed, especially when some adenovirus COVID-19 vaccination have been
410 suspended in many countries due to severe adverse effects⁵⁶.

411 Our findings are useful for designing and modifying effective vaccination promotion strategies and
412 immunization coverage programs for the public and those with vaccine hesitancy, based on different
413 national conditions and contextual backgrounds. Firstly, the perceived risks for infections and risks for
414 severe health problems secondary to the infection may be vital for the respondents actively to be
415 vaccinated. Hence the risks for the infection and the adverse outcomes secondary to the infection should
416 be clearly delivered by media or governments to the public to enhance mutual understanding. Secondly,
417 the vaccine price should be affordable and available for the public, and it is auspicious that many
418 countries have been making COVID-19 vaccines free of charge for the public⁵⁷⁻⁵⁹. Moreover,
419 monitoring information about vaccine safety should be made public on a regular basis after the
420 application of the vaccine, and timely health education and communication conducted by authoritative
421 sources^{44,60}.

422 Additionally, China and the US have plenty of differences, especially in contextual influences, for
423 instance, media environment, influential leaders, historical influences, policies, cultural factors, etc. As
424 the majority (82.0% for Chinese respondents, 72.2% for US respondents) of respondents generally
425 accept the COVID-19 vaccination, it is still worth efforts to further identify other barriers or facilitators
426 to their vaccination decision based on different contextual backgrounds and different countries.

427 Although the average COVID-19 vaccines acceptance of respondents from the US may be relatively
428 lower than those from China, higher annual income was associated with higher vaccine hesitancy among
429 US respondents. The respondents with higher educational level may tend to acknowledge more vaccines
430 risks.

431

432 ***Strength and limitations***

433 The present study has limitations. The inherent nature of cross-sectional studies renders it difficult to
434 establish causality or to generalize the results in a long-term manner, especially when vaccination
435 acceptance is variable, dynamic and multifactorial. Hence the results of the study should be interpreted
436 with cautions. But the present study implemented the PSM to minimize the confounding effects, and it
437 may somehow enhance the interpretability of the results.

438 Still, the present study is the first study to directly compare the acceptance and preference of the
439 respondents from two distinctly different representative countries, and the results of the study may
440 provide insights for the vaccination promotion strategy based on different national situations globally.

441 And the present study used multiple study methods to provide the most comprehensive and updated
442 investigation, especially on the influencing factors contributing to the decision making about
443 vaccination.

444 In conclusion, great variability in the preference of COVID-19 vaccines was found between
445 respondents from China and the United States, and the influencing factors for the hesitancy as well as
446 the attributes for their preferences for the vaccines varied, hence multi-disciplinary and international
447 collaboration should be established and strengthened based on specific national conditions to further
448 reduce vaccine hesitancy and increase vaccination coverage.

449 **Acknowledgments**

451 **Author contributions:**

453 Conceptualization: TRL, ZLH, WKM

454 Methodology: TRL, ZLH, JH, NY

455 Investigation: TRL, ZLH, QC, FQH, YZ, OMA, WKM, YBW

456 Visualization: TRL, ZLH, NY

457 Supervision: WKM, YBW

458 Writing—original draft: TRL, ZLH

459 Writing—review & editing: TRL, ZLH, JH, NY, BA, CJPZ

460 **Competing interests:** The author declared no competing interests.

463 **Data and materials availability:**

464 Data can be achieved via emailing to: wkming@connect.hku.hk

466 **Ethical approval**

467 This study has received the ethical approval at Jinan University Medical Ethics Committee. The
468 approval code is JNUKY-2021-004

470 **Funding**

471 No funding received in this work

473 **Figures and Tables**

475 **Fig. 1. The flow chart of propensity score matching.**

476 **Fig 2. COVID-19 vaccination acceptance comparison between China and the US after propensity**
477 **score matching.**

478 **Fig 3. The relative importance of COVID-19 vaccines attributes comparison between respondents**
479 **from the US and China.**

480 **Table 1. Participants' demographic information, major source of information and acceptance**

481 **Table 2. Comparison between the US and China in attributes levels utility and odds ratios.**

482 **Table 3. Share of preference and scenario analysis results**

483 **Supplementary Materials**

484

485 **Fig S1. COVID-19 vaccination acceptance comparison between China and the US depending on**
486 **sex, and age intervals after propensity score matching**

487 **Fig S2. COVID-19 vaccination acceptance comparison between China and the US depending on**
488 **education and annual income after propensity score matching**

489 **Fig S3. COVID-19 vaccination acceptance comparison between China and the US depending on**
490 **occupation after propensity score matching**

491 **Fig S4. COVID-19 vaccination acceptance in China before propensity score matching**

492 **Fig S5. COVID-19 vaccination acceptance in the US before propensity score matching**

493 **Fig S6. COVID-19 vaccination preference comparison between China and the US depending on**
494 **sex after propensity score matching**

495 **Table S1. Behavioral and psychological results**

496 **Table S2. The attributes and levels of vaccine acceptance and preference.**

497 **Table S3. The Pearson Correlation matrix between the baseline characteristics and acceptance**

498

499 **Reference**

500 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
501 in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.

502 2. Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the
503 2020 novel coronavirus epidemic in China. *J Autoimmun* 2020; **109**: 102434.

504 3. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel
505 coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;
506 **395**(10223): 514-23.

507 4. Imai N, Gaythorpe KAM, Abbott S, et al. Adoption and impact of non-pharmaceutical
508 interventions for COVID-19. *Wellcome Open Res* 2020; **5**: 59.

509 5. WHO. Timeline: WHO's COVID-19 response.

510 6. Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19
511 in the United States. *Nat Med* 2020; **26**(8): 1212-7.

512 7. Sarun Charumilind MC, Jessica Lamb, Adam Sabow, and Matt Wilson. When will the COVID-
513 19 pandemic end? 2021.

514 8. Worldometer. Countries where COVID-19 has spread. 2021.

515 9. WHO. WHO Coronavirus (COVID-19) Dashboard.

516 10. Ferguson N. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19
517 mortality and healthcare demand. 2020.

518 11. Coclite D, Napoletano A, Gianola S, et al. Face Mask Use in the Community for Reducing the
519 Spread of COVID-19: A Systematic Review. *Front Med (Lausanne)* 2020; **7**: 594269.

520 12. Fong MW, Gao H, Wong JY, et al. Nonpharmaceutical Measures for Pandemic Influenza in
521 Nonhealthcare Settings-Social Distancing Measures. *Emerg Infect Dis* 2020; **26**(5): 976-84.

- 522 13. Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Centre for the Mathematical
523 Modelling of Infectious Diseases C-wg. Effects of non-pharmaceutical interventions on COVID-19
524 cases, deaths, and demand for hospital services in the UK: a modelling study. *Lancet Public Health*
525 2020; **5**(7): e375-e85.
- 526 14. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. *JAMA*
527 2020; **323**(24): 2458-9.
- 528 15. Prevention CfDCa. Different COVID-19 vaccines. 2021.
- 529 16. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-
530 CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled,
531 phase 1/2 clinical trial. *Lancet Infect Dis* 2021; **21**(2): 181-92.
- 532 17. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. *Lancet* 2021;
533 **397**(10275): 642-3.
- 534 18. Remmel A. COVID vaccines and safety: what the research says. *Nature* 2021.
- 535 19. Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination.
536 *BMJ* 2021; **372**: n149.
- 537 20. Times G. Sinovac's COVID-19 vaccine 78% effective in phase 3 trial in Brazil. 2021.
- 538 21. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. *Nat Med*
539 2021; **27**(2): 205-11.
- 540 22. Malcom K. Overcoming COVID-19 Vaccine Hesitancy. 2021.
- 541 23. CDC. About Variants of the Virus that Causes COVID-19. 2021.
542 <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html>.
- 543 24. CDC. Science Brief: Emerging SARS-CoV-2 Variants. 2021.
- 544 25. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-
545 19 vaccine. *Nat Med* 2021; **27**(2): 225-8.
- 546 26. Lin C, Tu P, Beitsch LM. Confidence and Receptivity for COVID-19 Vaccines: A Rapid
547 Systematic Review. *Vaccines (Basel)* 2020; **9**(1).
- 548 27. Lew L. China's low vaccination rate risks delaying return to normal, warns leading medical
549 expert Zhong Nanshan. 2021. [https://www.scmp.com/news/china/science/article/3126296/chinas-low-
550 vaccination-rate-risks-delaying-return-normal-warns](https://www.scmp.com/news/china/science/article/3126296/chinas-low-vaccination-rate-risks-delaying-return-normal-warns).
- 551 28. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine
552 Acceptance Rates. *Vaccines (Basel)* 2021; **9**(2).
- 553 29. Volpp KG, Loewenstein G, Buttenheim AM. Behaviorally Informed Strategies for a National
554 COVID-19 Vaccine Promotion Program. *JAMA* 2021; **325**(2): 125-6.
- 555 30. McElveen CLaR. 10 reasons the US and China should cooperate now to stop the pandemic.
556 2021.
- 557 31. Yuan N. Reflections on China–US relations after the COVID-19 pandemic. *China International*
558 *Strategy Review* 2020; **2**(1): 14-23.
- 559 32. McCredie MN, Morey LC. Who Are the Turkers? A Characterization of MTurk Workers Using
560 the Personality Assessment Inventory. *Assessment* 2019; **26**(5): 759-66.
- 561 33. Randolph J, Falbe K, Manuel AK, Balloun JL. A step-by-step guide to propensity score
562 matching in R. *Pract Assess Res Eval* 2014; **19**: 1-6.
- 563 34. Lighthouse Studio Software. Share of Preference Option.
564 https://sawtoothsoftware.com/help/lighthouse-studio/manual/hid_shareofpreference.html
- 565 35. Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 Vaccination during the COVID-19
566 Pandemic in China. *Vaccines (Basel)* 2020; **8**(3).


- 567 36. S C. Why only half of Americans say they would get a COVID-19 vaccine. *Popular Science*
568 2020.
- 569 37. Kreps S, Prasad S, Brownstein JS, et al. Factors Associated With US Adults' Likelihood of
570 Accepting COVID-19 Vaccination. *JAMA Netw Open* 2020; **3**(10): e2025594.
- 571 38. Gypsyamber D Souza DD. What is herd immunity and how can we achieve it with COVID-19.
572 *Johns Hopkins Bloomberg School of Public Health Expert Insights* 2020.
- 573 39. Goldstein A CS. 7 in 10 Americans would be likely to get a coronavirus vaccine, Post-ABC poll
574 finds. . *Washington Post* 2020.
- 575 40. Wong MCS, Wong ELY, Huang J, et al. Acceptance of the COVID-19 vaccine based on the
576 health belief model: A population-based survey in Hong Kong. *Vaccine* 2021; **39**(7): 1148-56.
- 577 41. McFadden SM, Malik AA, Aguolu OG, Willebrand KS, Omer SB. Perceptions of the adult US
578 population regarding the novel coronavirus outbreak. *PLoS One* 2020; **15**(4): e0231808.
- 579 42. Nguyen T, Henningsen KH, Brehaut JC, Hoe E, Wilson K. Acceptance of a pandemic influenza
580 vaccine: a systematic review of surveys of the general public. *Infect Drug Resist* 2011; **4**: 197-207.
- 581 43. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: a critical review.
582 *Soc Sci Med* 2014; **112**: 1-11.
- 583 44. Dubé EMNE. Vaccine Acceptance: Barriers, Perceived Risks, Benefits, and Irrational Beliefs.
584 2nd ed ed. Cambridge, MA, USA: Academic Press: Cambridge, MA, USA; 2016.
- 585 45. Seale H, Heywood AE, McLaws ML, et al. Why do I need it? I am not at risk! Public
586 perceptions towards the pandemic (H1N1) 2009 vaccine. *BMC Infect Dis* 2010; **10**: 99.
- 587 46. Lau JT, Yeung NC, Choi KC, Cheng MY, Tsui HY, Griffiths S. Factors in association with
588 acceptability of A/H1N1 vaccination during the influenza A/H1N1 pandemic phase in the Hong Kong
589 general population. *Vaccine* 2010; **28**(29): 4632-7.
- 590 47. Zijtregtop EA, Wilschut J, Koelma N, et al. Which factors are important in adults' uptake of a
591 (pre)pandemic influenza vaccine? *Vaccine* 2009; **28**(1): 207-27.
- 592 48. China NHCopsRo. Vaccination status. 2021.
593 http://www.nhc.gov.cn/xcs/yqfkdt/gzbd_index.shtml.
- 594 49. NewsPoints F. Fauci says herd immunity could require nearly 90% to get coronavirus vaccine.
595 2020. <https://www.firstwordpharma.com/node/1786647>.
- 596 50. Jr. DGM. How Much Herd Immunity Is Enough? 2021.
597 <https://www.nytimes.com/2020/12/24/health/herd-immunity-covid-coronavirus.html>.
- 598 51. CDC. COVID Data Tracker. 2021. <https://covid.cdc.gov/covid-data-tracker/#vaccinations>.
- 599 52. Finance S. Not being vaccinated is very dangerous and will suffer! Latest reminder from Zhong
600 Nanshan and Zhang Wenhong. 2021. [https://finance.sina.com.cn/chanjing/cyxw/2021-03-31/doc-
601 ikmxzfm9945586.shtml](https://finance.sina.com.cn/chanjing/cyxw/2021-03-31/doc-ikmxzfm9945586.shtml).
- 602 53. Eskola J, Duclos P, Schuster M, MacDonald NE. How to deal with vaccine hesitancy? *Vaccine*
603 2015; **33**(34): 4215-7.
- 604 54. Nowak GJ, Gellin BG, MacDonald NE, Butler R. Addressing vaccine hesitancy: The potential
605 value of commercial and social marketing principles and practices. *Vaccine* 2015; **33**(34): 4204-11.
- 606 55. Bump JB, Friberg P, Harper DR. International collaboration and covid-19: what are we doing
607 and where are we going? *BMJ* 2021; **372**: n180.
- 608 56. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports
609 of blood clots. *BMJ* 2021; **372**: n699.
- 610 57. Determann D, Korfage IJ, Lambooi MS, et al. Acceptance of vaccinations in pandemic
611 outbreaks: a discrete choice experiment. *PLoS One* 2014; **9**(7): e102505.
- 612 58. WHO. Report of the SAGE Working Group on Vaccine Hesitancy.

- 613 59. Net X. China to Make COVID-19 Vaccine Global Public Good. 2020.
614 60. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy
615 around vaccines and vaccination from a global perspective: a systematic review of published literature,
616 2007-2012. *Vaccine* 2014; **32**(19): 2150-9.

617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636


Figures and tables

Fig 1. The flow chart of propensity score matching



637
638
639
640
641
642
643
644
645
646
647
648
649
650
651



Fig 2. COVID-19 vaccination acceptance comparison between China and the US after propensity score matching



652
653
654
655
656
657
658
659
660
661
662
663
664
665
666

^a Social cues in this study means social factors that potentially impact respondents' acceptance, i.e., recommendations from friends, family members, or employers, etc.

Fig 3. The relative importance of COVID-19 vaccines attributes comparison between respondents from the US and China



669
670
671
672
673
674

Table 1. Participants' demographic information, major source of information and acceptance

	Unmatched			Matched		
	China	The United States	<i>P</i> value	China	The United States	<i>P</i> value
Sample size n	5374	3701		1240	1240	
Sex (%)						
Male	2385 (44.4%)	1765 (47.7%)	0.003	534 (43.1%)	535 (43.1%)	1.00
Female	2971 (55.3%)	1918 (51.8%)		706 (56.9%)	705 (56.9%)	
Other	18 (0.3%)	18 (0.5%)		0 (0.0%)	0 (0.0%)	
Age interval in years (%)						
18-25	1119 (20.8%)	501 (13.5%)	<0.001	164 (13.2%)	162 (13.1%)	1.00
26-30	759 (14.1%)	762 (20.6%)		235 (19.0%)	234 (18.9%)	
31-35	697 (13.0%)	750 (20.3%)		244 (19.7%)	251 (20.2%)	
36-40	488 (9.1%)	505 (13.6%)		152 (12.3%)	152 (12.3%)	
41-45	514 (9.6%)	368 (9.9%)		139 (11.2%)	136 (11.0%)	
46-50	630 (11.7%)	241 (6.5%)		105 (8.5%)	103 (8.3%)	
51-55	429 (8.0%)	174 (4.7%)		89 (7.2%)	84 (6.8%)	
56-60	347 (6.5%)	154 (4.2%)		60 (4.8%)	60 (4.8%)	
Above 60	391 (7.3%)	246 (6.6%)		52 (4.2%)	58 (4.7%)	
Highest educational level (%)						
Pre-primary education or primary school education	399 (7.4%)	2 (0.1%)	<0.001	Non-postgraduate 1221 (98.5%)	Non- postgraduate 1222 (98.5%)	0.87
Middle school education	591 (11.0%)	15 (0.4%)				
High school education	933 (17.4%)	675 (18.2%)				
Vocational school education	887 (16.5%)	508 (13.7%)				
Bachelor's degree	2021 (37.6%)	1710 (46.2%)				
Master's degree	422 (7.9%)	711 (19.2%)				
PhD degree	121 (2.3%)	80 (2.2%)				
Occupation and working area (%)						
Students	1230 (22.9%)	249 (6.7%)	<0.001	139 (11.2%)	132 (10.6%)	1.00
Managers	681 (12.7%)	541 (14.6%)		178 (14.4%)	174 (14.0%)	

Professionals	768 (14.3%)	993 (26.8%)		250 (20.2%)	250 (20.2%)	
Technicians and associate professionals	795 (14.8%)	423 (11.4%)		148 (11.9%)	157 (12.7%)	
Clerical support workers	230 (4.3%)	318 (8.6%)		121 (9.8%)	122 (9.8%)	
Service and sales workers	515 (9.6%)	453 (12.2%)		185 (14.9%)	188 (15.2%)	
Skilled agricultural, forestry and fishery workers	373 (6.9%)	43 (1.2%)		14 (1.1%)	14 (1.1%)	
Craft and related trade workers	121 (2.3%)	78 (2.1%)		27 (2.2%)	28 (2.3%)	
Plant and machine operators and assemblers	184 (3.4%)	32 (0.9%)		11 (0.9%)	11 (0.9%)	
Elementary occupations	133 (2.5%)	75 (2.0%)		16 (1.3%)	14 (1.1%)	
Armed forces occupations	73 (1.4%)	19 (0.5%)		6 (0.5%)	4 (0.3%)	
Other	271 (5.0%)	477 (12.9%)		145 (11.7%)	146 (11.8%)	
Annual salary level (%)						
Under 10,000 USD	2254 (48.0%)	398 (11.0%)	<0.001	335 (27.0%)	333 (26.9%)	1.00
10,001-20000 USD	1225 (26.1%)	382 (10.6%)		257 (20.7%)	259 (20.9%)	
20,001-30,000 USD	561 (12.0%)	481 (13.3%)		236 (19.0%)	236 (19.0%)	
30,001-40,000 USD	296 (6.3%)	472 (13.1%)		192 (15.5%)	193 (15.6%)	
40,001-50,000 USD	163 (3.5%)	456 (12.6%)		91 (7.3%)	92 (7.4%)	
50,001-60,000 USD	55 (1.2%)	464 (12.8%)		41 (3.3%)	40 (3.2%)	
60,001-70,000 USD	46 (1.0%)	331 (9.2%)		23 (1.9%)	24 (1.9%)	
Above 70,000 USD	94 (2.0%)	630 (17.4%)		65 (5.2%)	63 (5.1%)	
Acceptance of vaccination (totally unwilling 0 ~ totally willing 10)						
Average	7.8 (2.5)	7.2 (3.5)	<0.001	7.8 (2.4)	6.9 (3.5)	<0.001
Acceptance of vaccination if someone else recommend (totally unwilling 0 ~ totally willing 10)						
Average	7.8 (2.5)	7.2 (3.3)	<0.001	7.8 (2.3)	6.9 (3.5)	<0.001
Self ever infected with COVID-19 (%)						
Yes	56 (1.0%)	569 (15.4%)	<0.001	21 (1.7%)	194 (15.6%)	<0.001
No	5243 (97.6%)	3102 (83.8%)		1196 (96.5%)	1033 (83.3%)	
Not to answer	75 (1.4%)	30 (0.8%)		23 (1.9%)	13 (1.0%)	
Friend family or community ever infected (%)						
Yes	149 (2.8%)	2575 (69.6%)	<0.001	47 (3.8%)	815 (65.7%)	<0.001
No	5110 (95.1%)	1096 (29.6%)		1156 (93.2%)	415 (33.5%)	
Not to answer	115 (2.1%)	30 (0.8%)		37 (3.0%)	10 (0.8%)	
Marital state (%)						

Single	1830 (34.1%)	1391 (37.6%)		372 (30.0%)	522 (42.1%)	
Married	3107 (57.8%)	1905 (51.5%)		739 (59.6%)	577 (46.5%)	
Divorced	185 (3.4%)	273 (7.4%)	<0.001	58 (4.7%)	98 (7.9%)	<0.001
Other	67 (1.2%)	109 (2.9%)		16 (1.3%)	38 (3.1%)	
Not to answer	185 (3.4%)	23 (0.6%)		55 (4.4%)	5 (0.4%)	
Source of information of COVID-19 vaccines (%)						
Healthcare provider	1844 (34.3%)	1294 (35.0%)	0.52	433 (34.9%)	387 (31.2%)	0.050
CDC or public health department	2464 (45.9%)	1958 (52.9%)	<0.001	583 (47.0%)	612 (49.4%)	0.24
News reports	3907 (72.7%)	2333 (63.0%)	<0.001	908 (73.2%)	773 (62.3%)	<0.001
Social media	2720 (50.6%)	1490 (40.3%)	<0.001	645 (52.0%)	505 (40.7%)	<0.001
Friends or family members	2065 (38.4%)	1199 (32.4%)	<0.001	431 (34.8%)	380 (30.6%)	0.029
Employers	422 (7.9%)	457 (12.3%)	<0.001	112 (9.0%)	110 (8.9%)	0.89
Pharmaceutical company advertisement	432 (8.0%)	123 (3.3%)	<0.001	100 (8.1%)	41 (3.3%)	<0.001
Other	14 (0.3%)	54 (1.5%)	<0.001	4 (0.3%)	17 (1.4%)	0.004

16
17

Table 2. Comparison between the US and China in attributes levels utility and odds ratios

Attributes	Variable	The US (n=1240)					China (n=1240)				
		Coefficient	Std Error	OR	95% CI	P value	Coefficient	Std Error	OR	95% CI	P value
Varieties	mRNA	Reference									
	Adenovirus vector vaccines	0.006	0.019	0.940	(0.906 - 0.976)	0.761	-0.105	0.018	0.922	(0.890 - 0.954)	<0.001
	Inactivated vaccine	-0.073	0.019	0.869	(0.837 - 0.902)	<0.001	0.128	0.018	1.164	(1.124 - 1.205)	<0.001
Adverse effect	very mild	Reference									
	mild	0.070	0.019	1.013	(0.976 - 1.051)	<0.001	0.077	0.018	0.879	(0.849 - 0.910)	<0.001
	moderate	-0.128	0.019	0.831	(0.800 - 0.863)	<0.001	-0.284	0.018	0.612	(0.591 - 0.635)	<0.001
Efficacy	55%	Reference									
	65%	-0.516	0.028	1.213	(1.147 - 1.282)	<0.001	-0.246	0.025	1.088	(1.036 - 1.144)	<0.001
	75%	0.061	0.029	2.158	(2.038 - 2.285)	0.038	0.048	0.028	1.461	(1.384 - 1.543)	0.084
	85%	0.438	0.025	3.146	(2.994 - 3.306)	<0.001	0.204	0.024	1.707	(1.627 - 1.791)	<0.001
	95%	0.726	0.027	4.196	(3.980 - 4.424)	<0.001	0.326	0.026	1.928	(1.832 - 2.030)	<0.001
Time for the vaccine starting working	5 days	Reference									
	10 days	-0.035	0.024	0.904	(0.863 - 0.948)	0.142	0.021	0.022	1.025	(0.982 - 1.069)	0.324
	15 days	0.017	0.023	0.953	(0.912 - 0.996)	0.445	-0.027	0.022	0.976	(0.936 - 1.019)	0.217
	20 days	-0.048	0.025	0.893	(0.849 - 0.938)	0.060	0.008	0.024	1.011	(0.965 - 1.059)	0.732
The duration of vaccine works	5 months	Reference									
	10 months	-0.081	0.024	1.148	(1.096 - 1.202)	<0.001	-0.021	0.022	1.153	(1.105 - 1.204)	0.338
	15 months	0.131	0.024	1.419	(1.354 - 1.487)	<0.001	0.048	0.023	1.236	(1.182 - 1.292)	0.035
	20 months	0.169	0.023	1.475	(1.410 - 1.543)	<0.001	0.136	0.022	1.350	(1.293 - 1.409)	<0.001
The cost of vaccination	\$0	Reference									
	\$50	0.179	0.026	0.674	(0.640 - 0.709)	<0.001	0.162	0.025	0.776	(0.740 - 0.814)	<0.001
	\$100	-0.111	0.026	0.504	(0.479 - 0.530)	<0.001	-0.029	0.024	0.641	(0.612 - 0.672)	0.225
	\$150	-0.263	0.029	0.433	(0.409 - 0.458)	<0.001	-0.200	0.027	0.540	(0.513 - 0.570)	<0.001
	\$200	-0.381	0.031	0.385	(0.362 - 0.409)	<0.001	-0.349	0.029	0.466	(0.440 - 0.493)	<0.001


18
19
20
21

12 **Table 3. Share of preference and scenario analysis results**

The US									
	Base scenario	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5	Scenario 6	Scenario 7	Scenario 8
Vaccine varieties	Inactivated vaccine	Adenovirus vaccine	mRNA	mRNA	Inactivated vaccine	Adenovirus vaccine	Adenovirus vaccine	Adenovirus vaccine	mRNA
Adverse effect	moderate	Very mild	Moderate	Mild	Very mild	Mild	Very mild	Very mild	Very mild
Efficacy	55%	75%	95%	95%	75%	95%	65%	75%	95%
Time for the vaccine starting working	20 days	20 days	20 days	20 days	10 days	20 days	5 days	5 days	5 days
The duration of vaccine works	5 months	5 months	5 months	5 months	5 months	5 months	5 months	5 months	20 months
The cost of vaccination	\$50	\$50	\$50	\$50	\$50	\$50	\$50	\$50	\$50
Share of preference	2.9%	8.2%	14.2%	17.3%	7.7%	16.2%	5.2%	9.2%	19.1%
China									
Vaccine varieties	Adenovirus vaccine	Adenovirus vaccine	mRNA vaccine	mRNA vaccine	Inactivated vaccine	Adenovirus vaccine	Adenovirus vaccine	Adenovirus vaccine	Inactivated vaccine
Adverse effect	moderate	Very mild	Moderate	Mild	Very mild	Mild	Very mild	Very mild	Very mild
Efficacy	55%	75%	95%	95%	75%	95%	65%	75%	95%
Time for the vaccine starting working	20 days	20 days	20 days	20 days	10 days	20 days	5 days	5 days	5 days
The duration of vaccine works	5 months	5 months	5 months	5 months	5 months	5 months	5 months	5 months	20 months
The cost of vaccination	\$50	\$50	\$50	\$50	\$50	\$50	\$50	\$50	\$50
Share of preference	4.5%	10.7%	9.4%	13.4%	13.7%	12.4%	7.9%	10.6%	17.6%

medRxiv preprint doi: <https://doi.org/10.1101/2021.04.29.21256317>; this version posted May 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

13
14







Vaccine hesitancy




Vaccine acceptance





The US



China